Document is current

Article History

Received: 20 February 2024

Revised: 3 September 2024

Accepted: 10 September 2024

First Online: 3 October 2024

Declarations

:

: SS, ND, MO, TK, TIshikawa and TIkeda have nothing to disclose. KF and MT received honoraria from Janssen. YO received honoraria from Novartis, Pfizer, Janssen, AsahiKasei, Abbvie, Astellas, Amgen, Chugai, Bristol-Myers Squibb, Symbio, MSD, Meiji Seika, Sumitomo Dainippon, Daiichi Sankyo, Nippon Shinyaku, IQVIA, KISSEI and Kyowa Kirin; research funding from Novartis, Pfizer, Janssen, Meiji Seika, Incyte, and Takara Bio. TG received honoraria from Novartis and Mallinckrodt. HN received honoraria from Novartis, Janssen, Chugai, Astellas, Bristol-Myers Squibb and Takeda; research funding from Novartis, Astellas, Bristol-Myers Squibb and Takeda. YM received research funding from from Asahi Kasei, Eisai, Otsuka, Kyowa Kirin, Taiho, Takeda, Chugai, Japan blood products, Nippon Kayaku, Nippon Shinyaku, Mallinckrodt, and Regimmune; and honoraria from Asahi Kasei, AstraZeneca, Astellas, Amgen, AbbVie, Viatris, Eisai, MSD, Otsuka, ONO, Gilead, Kyorin, Kyowa, Kissei, Konica, Sanofi, Celgene, Bristol-Myers Squibb, Bayer, CSL Behring, Daiichi Sankyo, Sumitomo Dainippon, Takeda, Terumo, Chugai, Nippon Shinyaku, Novartis, Pfizer, Mundipharma, Human Life CORD, Meiji Seika, Janssen and Yakult Honsha. KK received consulting fees from AbbVie, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Janssen, and Novartis; honoraria from Bristol-Myers Squibb, Chugai, Sumitomo Pharma Co., Ltd., Janssen, Kyowa Kirin, MSD, Novartis and ONO; and research funding from AbbVie, MSD, Bristol-Myers Squibb, Janssen, Novartis, Chugai, Daiichi Sankyo, Eisai, Kyowa Kirin, and ONO. NU received honoraria from Novartis and Otsuka. AM, FS and TT are employees of Novartis Pharma K.K., Tokyo, Japan. TS is an employee of Novartis Pharma AG, Basel, Switzerland. TTeshima received honoraria from Novartis, Abbvie, Astellas, NIPPON SHINYAKU, Kyowa Kirin, Bristol-Myers Squibb, Sumitomo Pharma, Merck Sharp & Dohme, Celgene, Chugai, and Janssen; research funding from Astellas, Chugai, Fuji Pharma, Kyowa Kirin, Nippon Shinyaku, Asahi Kasei Pharma, Eisai, Sumitomo Pharma, ONO, Shionogi, Priothera SA, LUCA science and Otsuka; advisory board fees from Meiji Seika Pharma, Daiichi Sankyo, Asahi Kasei Pharma, Astellas, AstraZeneca, Takeda, Janssen, Toche Diagnostics, Sumitomo Pharma, Celgene, and Sanofi.